Halozyme Therapeutics, Inc.HALONASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+10.5%
5Y CAGR+33.4%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+10.5%/yr
vs +24.0%/yr prior
5Y CAGR
+33.4%/yr
Recent deceleration
Acceleration
-13.5pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
4.2x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$193.39M+25.3%
2024$154.34M+3.5%
2023$149.18M+3.9%
2022$143.53M+185.2%
2021$50.32M+10.0%
2020$45.74M-40.8%
2019$77.25M+27.1%
2018$60.80M+13.0%
2017$53.82M+17.4%
2016$45.85M-